Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G8ZQ
|
|||
| Former ID |
DIB008087
|
|||
| Drug Name |
G17DT
|
|||
| Synonyms |
Gastrimmune; Insegia
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 3 | [1] | |
| Company |
Receptor Biologix
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastrin (GAST) | Target Info | . | [2] |
| KEGG Pathway | Gastric acid secretion | |||
| Panther Pathway | CCKR signaling map ST | |||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | G alpha (q) signalling events | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| Gastric acid production | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02118077) Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.